Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients.
Edwards had told investors in December 2023 that it planned to spin off the business in order to focus more sharply on addressing structural defects in the heart. BD, meanwhile, wants to increase its monitoring presence in hospitals. In a statement announcing the acquisition, the company touted the “advanced AI algorithms” used in Edwards’ monitors.
advertisement
BD CEO Tom Polen said in a statement that the acquisition will bolster BD’s portfolio of “AI-enabled clinical decision tools” and digital health products in general.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get Started
Totals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get Started
Then $39/month
Annual
$399
Save 15%
$399/year Get Started
Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A Quote
Savings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started
$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
